Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Akili (AKLI – Research Report) today and set a price target of $3.00. The company’s shares opened today at $1.31.
Purohit covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Axsome Therapeutics, and Kymera Therapeutics. According to TipRanks, Purohit has an average return of -24.1% and a 17.65% success rate on recommended stocks.
Akili has an analyst consensus of Moderate Buy, with a price target consensus of $2.37.
See Insiders’ Hot Stocks on TipRanks >>
AKLI market cap is currently $114.5M and has a P/E ratio of -5.62.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Social Capital Suvretta Holdings Corp I is a blank check company.
Read More on AKLI:
